U.S. Markets closed

AzurRx BioPharma, Inc. (AZRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.4500+0.0700 (+2.07%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.3800
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range3.3800 - 3.6600
52 Week Range3.3600 - 26.3000
Avg. Volume665,063
Market Cap271.084M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-1.8700
Earnings DateAug 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
  • GlobeNewswire

    AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

    Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it will begin operating under its new corporate name, First Wave BioPharma, Inc., effective today upon the completion of cer

  • Benzinga

    36 Stocks Moving In Tuesday's Mid-Day Session

    Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock. BTCS Inc. (NASDAQ: BTCS) shares climbed 23% to $10.25 as the company commenced trading on The Nasdaq Capital Market. Comm

  • Zacks

    AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M

    AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.